ORIGINAL RESEARCH article
Front. Pediatr.
Sec. Pediatric Nephrology
Dimethylarginines in Pediatric CKD: Clinical Utility of ADMA and SDMA as Biomarkers
Provisionally accepted
- 1Faculty of Medicine, Ondokuz Mayıs University, Samsun, Türkiye
- 2TC Saglik Bakanligi Ordu Egitim ve Arastirma Hastanesi, Ordu, Türkiye
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Pediatric chronic kidney disease (CKD) often presents no symptoms in its early stages, making timely diagnosis challenging. Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) are methylated arginine derivatives that reduce nitric oxide availability and have been suggested as potential early indicators of kidney dysfunction. This study aimed to evaluate the usefulness of ADMA and SDMA in pediatric CKD and to assess their association with renal function and disease severity. Methods: This single-center, cross-sectional, observational study enrolled 100 children aged 1– 18 with CKD stages 2–4 and 70 healthy, age-and sex-matched controls between January and September 2023. Serum ADMA and SDMA levels were measured using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-ESI-MS/MS). The estimated glomerular filtration rate (eGFR) was calculated using the Schwartz formula. Comparisons were made between groups and CKD stages, and correlation analyses were conducted with eGFR. Results: ADMA and SDMA levels were significantly higher in the CKD group than in the control group (p < 0.001 and p = 0.013, respectively), while the ADMA/SDMA ratio showed no significant difference. ADMA levels increased progressively with CKD stage, particularly in stage 4 patients (p < 0.001). There were moderate negative correlations between eGFR and both ADMA (r = −0.380, p < 0.001) and SDMA (r = −0.238, p = 0.002). These findings suggest that both biomarkers increase with disease progression, with ADMA demonstrating moderate associations. Conclusion: Serum ADMA and SDMA levels increase with worsening kidney function in children and may serve as useful markers associated with disease severity in pediatric CKD, but further validation is required. In particular, ADMA reflects disease severity and endothelial dysfunction, highlighting its potential role in clinical risk stratification.
Keywords: Chronic Kidney Disease, Pediatrics, biomarkers, Asymmetric dimethylarginine, Symmetric dimethylarginine
Received: 08 Jul 2025; Accepted: 24 Oct 2025.
Copyright: © 2025 Nalçacıoğlu, Cihan, Önal and Karalı. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hülya Nalçacıoğlu, hulyanalcacoglu@hotmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.